id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-D-0208-0002,FDA,FDA-2005-D-0208,"Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Draft Guidance Document",Other,GDL-Guidance (Supporting and Related Materials),2005-12-02T05:00:00Z,2005,12,,,2008-07-18T05:20:46Z,,0,0,090000648044123a
FDA-2005-D-0208-0001,FDA,FDA-2005-D-0208,"Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability",Notice,NAD-Notice of Availability of Data,2005-12-02T05:00:00Z,2005,12,2005-11-30T05:00:00Z,2006-03-02T04:59:59Z,2008-07-18T05:09:10Z,,0,0,0900006480441234